Radiotherapy Compared to Chemotherapy as Initial Treatment of Angiocentric Centrofacial Lymphoma (Polymorphic Reticulosis)

Sobrevilla-Calvo, Pedro; Meneses, Abelardo; Alfaro, P; Barés, Juan Pablo; Amador, Jaime; Reynoso, Eduardo

doi:10.3109/02841869309083888

Cited by 32 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with stage I/II disease, radiotherapy (RT) improved CR rates to 52–100% [25, 30, 31, 35, 37, 41–44]. Given the high rate of disease progression during standard CHOP chemotherapy (35%) as well as the previously documented superiority of CHOP-14 over standard CHOP by the German high-grade NHL study group [45, 46], two cycles of dose-intense CHOP every two weeks (DI-CHOP-14) followed by RT and consolidation therapy with four cycles of standard CHOP thereafter was investigated by Kim et al and Lee et al in patients with localized nasal NK/T-cell NHL [18, 47].…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

et al. 2011

View full text Add to dashboard Cite

Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4–50.7%) for enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0–75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year OS was 38.5% (95% CI 35.5–41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5–31.2%) for ETTL to 56.5% (95% CI 42.8–69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the benefits of anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes for these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…C/T alone also results in poor outcomes and may be inferior to R/T alone 33, 34. The combination of R/T and C/T has been applied widely in most centers for the treatment of patients with locoregional disease.…”

Section: Discussionmentioning

confidence: 99%

Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T‐cell or T‐cell lymphoma

Tien

Tang

et al. 2004

Cancer

172

150

View full text Add to dashboard Cite

BACKGROUND Sinonasal natural killer (NK)/T‐cell or T‐cell lymphoma behaves quite differently from other lymphomas. The objective of this study was to investigate clinical features, treatment outcomes, and failure patterns in patients with this type of sinonasal lymphoma. METHODS From September, 1977 to December, 2000, 77 patients with sinonasal NK/T‐cell lymphoma or T‐cell lymphoma who had received radiotherapy (R/T), chemotherapy (C/T), or both (R/T and C/T) were evaluated retrospectively. RESULTS Fifty‐six patients (73%) had locoregional disease only, and 21 patients (27%) had systemic involvement. Forty‐four patients (57%) achieved a complete remission (CR). The 5‐year overall survival rate was 36% (median follow‐up, 89 months). Achievement of CR was the only prognostic factor for survival in multivariate analysis. Among patients with locoregional disease, the CR rate was 63%, and the 5‐year overall survival rate was 42%. Combined R/T and C/T or R/T alone resulted in better survival compared with C/T alone (5‐year survival rates, 59%, 50%, and 15%, respectively; P = 0.01). Incidences of locoregional and systemic failure were 43% and 30%, respectively. Outcome was dismal for patients with systemic disease, with a CR rate of 43% and a 5‐year survival rate of 25%. Only 2 of 21 patients had sustained remissions. The locoregional and systemic failure rates were 57% and 71%, respectively. CONCLUSIONS Treatment outcomes were unsatisfactory for patients with locoregional and systemic sinonasal NK/T‐cell or T‐cell lymphoma. R/T could not control locoregional disease satisfactorily, and C/T was unable to eradicate systemic disease in many patients. High‐dose therapy may be worth studying in these patients. New treatments should be investigated to increase remission rates, prevent failure, and improve survival. Cancer 2004;100:366–75. © 2003 American Cancer Society.

show abstract

“…However, relapse in the extra‐irradiated regions has commonly been observed. The five‐year survival rate after chemotherapy varies from 14 to 100% (12, 15–17). The five‐year survival rate of the cases treated with chemotherapy followed by radiation therapy has been from 14 to 58% (12, 18, and 19).…”

Section: Discussionmentioning

confidence: 99%

Extra Nodal NK/T-Cell Lymphoma Nasal Type that Responded to DeVIC Combination Chemotherapy

Nomura

Isoda

Yamanaka

et al. 2005

The Journal of Dermatology

View full text Add to dashboard Cite

We report a 76-year-old woman with extra nodal NK/T-cell lymphoma nasal type (ENKL). She had large tumors on her left leg with inguinal lymphadenopathy and gastric tumors. The tumor cells showed angiocentric growth with necrosis. Immunohistologically, the tumor cells from the skin lesion expressed CD2, cytoplasmic CD3, CD56, and T-cell intracellular antigen-1 (TIA-1), but not surface CD3, CD19, and TdT. The gastric tumor cell, also expressed cytoplasmic CD3, CD45RO and CD56. She was diagnosed as having ENKL (stage IV of Ann Arbor). The tumors responded remarkably well to radiation therapy followed by multi-drug resistance independent DeVIC (carboplatin, etoposide, ifosfamide, and dexamethasone) combination therapy. After two series of this therapy, no tumors were detected in clinical, histopathological, endoscope and computerized tomogram (CT) examinations. However, she suddenly died of brain stem metastasis three months later. Although there may be a limitation of effects on metastasis of tumors in the central nervous system, radiation and DeVIC combination therapy is a potent therapeutic method for ENKL.

show abstract

Radiotherapy Compared to Chemotherapy as Initial Treatment of Angiocentric Centrofacial Lymphoma (Polymorphic Reticulosis)

Cited by 32 publications

References 20 publications

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T‐cell or T‐cell lymphoma

Extra Nodal NK/T-Cell Lymphoma Nasal Type that Responded to DeVIC Combination Chemotherapy

Contact Info

Product

Resources

About